The effect of theophylline and enprofylline on the late cutaneous response to antigen and compound [formula omitted

Abstract

Theophylline and enprofylline have been demonstrated to reduce mast cell-mediator release, inhibit polymorphonuclear leukocyte activation, and have been reported to reduce the late bronchial response to antigen. The effects of theophylline and enprofylline on the late cutaneous response (LCR) to compound 48 80 and antigen were studied in 29 patients enrolled in a placebo-controlled, double-blind study of the effect of the xanthines in mild asthma. Skin testing to a common environmental allergen and compound 48 80 was performed during a baseline period and in the second phase of the study after stable drug levels were achieved, at least 6 weeks later. During baseline, the mean immediate wheal diameter (IWD) with antigen was 15.7 mm ± 0.5, resulting in 27 29 LCRs with a mean wheal diameter of 37.1 mm ± 5.2. The mean IWD with compound 48 80 was 16.1 mm ± 0.7, resulting in 26 29 LCRs with a mean wheal diameter of 19.6 mm ± 2.8. Repeat skin testing during treatment revealed no statistically significant changes in the LCR elicited by antigen or 48 80 in any of the treatment groups. There was little correlation between the size of the immediate wheal produced by antigen or 48 80 and the resulting size of the late response ( r = 0.174 to 0.519). However, for the same IWD, the resulting late response was smaller with 48 80 than with antigen ( p = 0.003). We conclude that (1) theophylline and enprofylline have no effect on the LCR to 48 80 and antigen and (2) for equivalent immediate wheal sizes, the resulting late response is smaller with 48 80 than with antigen.